ArticleArchives of microbiology2026
Antibacterial activity of lantibiotics, alone and in combination with colistin, against Gram-negative bacteria.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In this study, the potential of the use of class I antimicrobial cationic peptides, also known as lantibiotics, nisin, warnerin and hominin, combined with subinhibitory concentrations of colistin against Gram-negative bacteria (GNB) was investigated. The minimum inhibitory concentration (MIC) and fractional inhibitory concentration index were determined via the microbroth dilution and checkerboard techniques, respectively. We showed synergistic effects of the combination of all the lantibiotics + colistin against Escherichia coli, Enterobacter aerogenes, Pseudomonas fluorescens, clinical multidrug-resistant Klebsiella pneumoniae, and multidrug-resistant Alcaligenes faecalis, whereas lantibiotics alone had no effect. In time‒kill curve studies, synergism was observed with almost all the expected combinations and was prolonged by N-ethylmaleimide, used solely as a mechanistic inhibitor of peptide degradation and not as a potential treatment. The maximum reduction exceeded 6 log CFU/mL compared to the control. Compared with no treatment, exposure to subMICs of colistin alone slightly increased membrane permeability, whereas treatment with the combination of warnerin and colistin caused more damage than did colistin alone. Energy dispersive X-ray spectroscopy revealed that pretreatment of cells with subMICs of colistin caused a decrease in the intracellular contents of Ca2+, Mg2+, phosphorus and sulfur, suggesting the possibility of implementing the antibacterial effects of lantibiotics during their subsequent action. The anti-infective activity of lantibiotics + colistin was demonstrated in Galleria mellonella larvae infected with E. aerogenes. We conclude that the synergistic antimicrobial activity of the combination of lantibiotic + colistin against GNB pathogens warrants further exploration for specific treatment of GNB infections.
Indexed as
Identifiers
41842969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.